Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Prostate Cancer

Faculty

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Hormonal Therapy for Nonmetastatic Hormone-Sensitive Prostate Cancer (nmHSPC)

• Rationale for the evaluation of treatment intensification with androgen receptor (AR) pathway inhibitors for patients with nmHSPC
• Key findings, including overall survival outcomes, with enzalutamide combined with leuprolide versus enzalutamide or leuprolide alone for men with nmHSPC and high-risk biochemical recurrence after definitive therapy
• FDA approval and optimal application of enzalutamide with and without androgen deprivation therapy (ADT) for nmHSPC
• Published data with ADT intensification with apalutamide with or without abiraterone for patients with high-risk biochemically recurrent nmHSPC

MODULE 2: Hormonal Therapy for Metastatic HSPC (mHSPC)

• Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for men with mHSPC
• Published data with the addition of darolutamide to ADT for patients with mHSPC; recent FDA approval of this regimen
• Clinical factors guiding the selection of a specific secondary hormonal agent for patients with mHSPC; available datasets exploring the relative benefit of the various approved therapies in this setting
• Published efficacy and safety data with darolutamide in combination with docetaxel and ADT for mHSPC; selection of optimal candidates for triplet therapy

MODULE 3: Tolerability of Hormonal Therapy for Prostate Cancer

• Incidence of hypertension and other cardiovascular (CV) adverse events (AEs) with different hormonal agents; optimal pretreatment assessment, on-therapy monitoring and management of CV events
• Spectrum and frequency of central nervous system-related AEs (eg, seizures, cognitive decline, falls, fatigue) observed with hormonal therapy for patients with prostate cancer
• Prevalence, mitigation and management of other notable side effects (eg, fractures, hot flashes, sarcopenias) with available hormonal therapies for prostate cancer
• Tolerability profile of enzalutamide with and without ADT for nmHSPC; differences, if any, in the experience with this agent in later settings

MODULE 4: Potential Role of Capivasertib in the Management of mHSPC

• Frequency of PTEN deficiency in patients with prostate cancer; optimal approach to assessment of PTEN status
• Biological justification for targeting the PI3K/AKT/mTOR pathway in prostate cancer, particularly in PTEN-deficient disease; mechanism of action of capivasertib
• Recently presented efficacy and safety results with the addition of capivasertib to abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
• Potential integration of capivasertib/abiraterone/ADT into treatment algorithms

MODULE 5: Tolerability Profile of Capivasertib

• Recommended side-effect management strategies for patients experiencing diarrhea and other gastrointestinal (GI) disorders while receiving capivasertib
• Incidence of hyperglycemia among patients receiving capivasertib; appropriate glucose monitoring and interventions for those with elevated blood glucose levels
• Optimal mitigation and management of cutaneous adverse reactions associated with capivasertib
• Appropriate monitoring of complete blood counts for patients receiving capivasertib; recommended dose modifications for those experiencing cytopenias

MODULE 6: Current and Future Role of PARP Inhibitors in Therapy for Metastatic Prostate Cancer

• Incidence and clinical implications of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in prostate cancer; recommended timing and optimal method for genetic testing
• Biological basis for combining PARP inhibitors with secondary hormonal therapies in metastatic prostate cancer
• Long-term efficacy and safety findings with olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC)
• FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide in mCRPC; optimal selection of patients for these approaches
• Recently presented data with the addition of niraparib to abiraterone/prednisone for patients with mHSPC harboring alterations in HRR genes; clinical implications and integration into treatment algorithms
• Other ongoing Phase III efforts evaluating combined PARP/AR pathway inhibition in this setting

MODULE 7: Tolerability of PARP Inhibitors Used for Prostate Cancer

• Incidence, timing and severity of common class-effect and agent-specific toxicities associated with PARP inhibitors for patients with metastatic prostate cancer
• Optimal monitoring and management strategies for PARP inhibitor-related toxicities
• Impact on the tolerability of PARP inhibitors when administered in combination with secondary hormonal therapy
• Strategies for identifying the root cause of toxicities in patients receiving PARP inhibitor/secondary hormonal therapy combinations that may be attributable to either agent

MODULE 8: Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Prostate Cancer

• Clinical relevance of PSMA expression in prostate cancer; mechanism of action of lutetium Lu 177 vipivotide tetraxetan
• Published datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated PSMA-positive mCRPC
• Appropriate sequencing of lutetium Lu 177 vipivotide tetraxetan with regard to other available therapies for mCRPC
• Recently presented data with the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC; implications for clinical practice

MODULE 9: Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan in Treatment for Metastatic Prostate Cancer

• Incidence, severity and management of commonly occurring AEs with radium-223 (eg, cytopenias, GI toxicity, peripheral edema, fractures)
• Recommended algorithms for the management of common AEs observed in patients receiving lutetium Lu 177 vipivotide tetraxetan (eg, fatigue, dry mouth, GI toxicity, cytopenias)
• Educating patients receiving radiopharmaceuticals regarding radiation risks and appropriate protection precautions
• Other practical considerations related to the administration of novel radiopharmaceuticals for prostate cancer (eg, locating and referring patients to a nuclear medicine treatment center)

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appraise published research findings on optimal management approaches for patients with biochemical recurrence following local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options.
• Evaluate the published research supporting the FDA approvals of secondary hormonal agents for nonmetastatic prostate cancer, and apply this information to educate patients about personalized treatment recommendations.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and identify patients for these strategies.
• Assess the available research supporting PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/ProstateCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Mr Lai and Ms Walker have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Yu — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Johnson & Johnson, Lantheus, Merck, Novartis, Samsung Bioepis, Tolmar; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Pfizer Inc, Tyra Biosciences Inc. 

MODERATOR
Dr Tagawa — Consulting Agreements: AbbVie Inc, Abdera Therapeutics, Bayer HealthCare Pharmaceuticals, Biohaven, Blue Earth Diagnostics, Boston Scientific Corporation, Clarity Pharmaceuticals, Convergent Therapeutics Inc, Daiichi Sankyo Inc, EMD Serono Inc, GE Healthcare, Gilead Sciences Inc, Johnson & Johnson, Lantheus, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Telix Pharmaceuticals Limited; Contracted Research: AIQ Solutions, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Gilead Sciences Inc, Janux Therapeutics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer Inc, Telix Pharmaceuticals Limited; Data and Safety Monitoring Boards/Committees: Boston Scientific Corporation; Stock OPTIONS — Private Companies: Convergent Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Merck, and Novartis.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.